Literature DB >> 22985209

Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study.

V Modesti, R Ramonda, A Ortolan, M Lorenzin, A Lo Nigro, P Frallonardo, F Oliviero, C Campana, L Punzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22985209     DOI： 10.3109/03009742.2012.698393

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN： 0300-9742            Impact factor:   3.641


× No keyword cloud information.
  5 in total

1.  Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C.

Authors:  Monica Salvi; Laura Macaluso; Cecilia Luci; Carlo Mattozzi; Giovanni Paolino; Yvonne Aprea; Stefano Calvieri; Antonio Giovanni Richetta
Journal:  World J Clin Cases       Date:  2016-02-16       Impact factor: 1.337

2.  Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients.

Authors:  Luisa Costa; Francesco Caso; Mariangela Atteno; Chiara Giannitti; Antonio Spadaro; Roberta Ramonda; Maristella Vezzù; Antonio Del Puente; Filomena Morisco; Ugo Fiocco; Mauro Galeazzi; Leonardo Punzi; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2013-08-24       Impact factor: 2.980

3.  Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab.

Authors:  Mariagrazia Lorenzin; Augusta Ortolan; Paola Frallonardo; Francesca Oliviero; Leonardo Punzi; Roberta Ramonda
Journal:  BMC Musculoskelet Disord       Date:  2015-07-24       Impact factor: 2.362

4.  Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis.

Authors:  Filomena Morisco; Maria Guarino; Serena La Bella; Luisa Di Costanzo; Nicola Caporaso; Fabio Ayala; Nicola Balato
Journal:  BMC Gastroenterol       Date:  2014-12-19       Impact factor: 3.067

5.  Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.

Authors:  Mariagrazia Lorenzin; Augusta Ortolan; Giacomo Cozzi; Antonia Calligaro; Maria Favaro; Teresa Del Ross; Andrea Doria; Roberta Ramonda
Journal:  Clin Rheumatol       Date:  2021-06-16       Impact factor: 2.980
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.